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Abstract 
 
 The skin is an ideal organ for the safe and convenient delivery of vaccines, small 
molecules, and other biologics. Members of the Irvine and Hammond groups have developed a 
polyelectrolyte multilayer thin film-coated microneedle platform that can achieve simultaneous 
DNA and nanoparticle delivery. This delivery platform has the advantage of direct delivery of 
DNA or polymer nanoparticles to immune-active cells at the interface between the dermis and 
epidermis, enhancing uptake of the delivered cargo by resident immune cells. Ideal for the 
delivery of DNA vaccines, this platform aims to bridge the gap in the lack of efficient delivery 
platforms hampering the effectiveness of DNA vaccines. The ability to co-deliver polymer 
nanoparticles can serve as a conduit for delivering immune stimulating adjuvants or other drugs 
for therapeutic applications.  
 An overview of current vaccine and delivery system research is presented. Market factors 
for the commercialization of the polyelectrolyte multilayer thin film-coated microneedle delivery 
platform are considered along with the risk factors in bringing this invention to market. An 
assessment of the intellectual property surrounding the platform is performed and a preliminary 
market entry strategy is developed for minimizing the risks commercialization. 
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1 Introduction 
 
Vaccination is undoubtedly one of the most significant advances in medical science to 
prevent infection-related morbidity and mortality. First documented in China as early as the 
10th century and implemented on a wide scale in 1796 by Edward Jenner for smallpox, 
vaccination is currently credited for preventing more than three million deaths per year 
worldwide 1 and attributed to a significant portion of the thirty year increase in human 
lifespan during the 20th century 2. Major triumphs such as the eradication of smallpox more 
than three decades ago and the inevitable eradication of polio 3-4 underscore the current 
efforts to replicate the experience from these successful campaigns to other diseases and 
infectious agents. 
 While the danger of a polio epidemic is waning, the threat of a human influenza 
pandemic is on the rise, with many experts predicting the imminent and inevitable spread of 
pandemic influenza 5. Major governments around the world have sought to prepare for an 
influenza pandemic by ordering millions of doses of vaccine to stockpile. However, with a 
worldwide production capacity of approximately 300 million doses per year, 6 the demand 
for vaccine would easily outstrip available and anticipated supplies for a rapidly mutating 
and contagious strain 7. In addition, current influenza vaccine production is haphazard, 
relying on a hit or miss approach of screening inoculated eggs for recombinant strains that 
can provide protection against circulating strains and can grow well in ova, lengthening the 
already long egg-based production process. A logical course of action to minimize this lag 
time is to stockpile vaccine; however, pandemic strains cannot be predicted with certainty 
and any advantage from a stockpile would be negated if forecasts were inaccurate. 
 Varying strategies have been put forth by the World Health Organization (WHO) in an 
attempt to alleviate vaccine supply problems including exchange of clinical trial data from 
different strains of influenza, development of antigen sparing strategies, increased funding 
and tax incentives for industry, and lowering regulatory licensing fees 8. However, none of 
these suggestions addresses the core problem: adequate supply of vaccine in times of high 
demand (Figure 1). While commercial processes of existing vaccine strategies such as 
attenuated, whole killed and subunit vaccines are well characterized, major issues such as 
the suitability of an unknown or poorly characterized pathogen for attenuation in the short 
term after an outbreak and the need for relatively higher dosing for clinical effect in whole 
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killed and subunit vaccines put considerable strain on the vaccine supply chain in the event 
of a pandemic outbreak. DNA vaccines have been proposed as an alternative to alleviate this 
production bottleneck. Mechanistically able to induce robust humoral and cellular responses 
in small animals, DNA vaccines also promise to alleviate issues related to mass production 
given existing robust cell-based and cell-free manufacturing capabilities. The success of the 
DNA vaccine platform has been demonstrated with products on the market approved for 
veterinary use in horses, dogs, pigs, and fish for varying indications such as West Nile virus 
and melanoma (Table 1). 
 
 
Figure 1: Manufacturing and production timeline for producing influenza vaccines in eggs 1 
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Table 1: DNA vaccines approved for use 9 
 
However, there have been difficulties during stage II and stage III clinical trials in 
replicating the robust responses seen in small animals that have been attributed to poor 
expression of the delivered plasmid 9. Nevertheless, the proven efficacy of the veterinary 
products on the market and positive results in ongoing human trials for melanoma and 
prostate cancer therapeutic DNA vaccines 9-11 demonstrate that focusing efforts to boost 
expression and response levels in humans is one of the keys to the success of the platform. 
Among the areas ripe for investigation include optimization of transcriptional elements for 
stronger transcription activity, gene optimization for more stable mRNA and more efficient 
translation, addition of formulation adjuvants in the delivery vehicle and on the plasmid to 
stimulate a more potent response, and optimizing the delivery method to increase cellular 
delivery of the plasmid (Figure 2).  
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Figure 2: Areas for improvement for the development of a DNA vaccine 9 
 
Focusing on the delivery of vaccines, intramuscular (IM) injection has been the most 
common route for administration. To induce a more potent immune response for DNA 
vaccines, studies have demonstrated the importance of transfecting antigen presenting cells 
(APCs) directly to engage both the endogenous and exogenous antigen presentation 
pathways for robust humoral and cellular responses 12-13. However, most DNA vaccine trials 
have been administered via intramuscular injection, a method that is known to transfect 
mostly myocytes 14 as opposed to APCs. The lack of available alternative delivery methods 
has spurred the development of innovative means for targeted delivery of DNA to APCs. 
One such alternative is the microneedle array, a device that is able to increase the 
permeability of the skin by piercing the stratum corneum with pain-free micrometer length 
projections. Once disrupted, the skin is drastically more amendable for delivery of small 
molecules and other agents. Current methods for microneedle delivery of bioactive 
molecules involve coating thin films of dried formulations on the surfaces of the 
microneedle array 15. While delivery is achieved, this coating method is notably limited in 
the range of molecules that can stay active after a drying process, especially for fragile 
bioactive molecules, and provides few means for controlling release kinetics 16.  
To address these issues, the Irvine and Hammond groups have devised a biodegradable 
polymer microneedle device with surfaces that allow layer-by-layer (LbL) deposition and 
self-assembly of polyelectrolyte films for concurrent delivery of nanoparticles (NP) and 
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plasmid DNA 17. Using the mild aqueous conditions for building polyelectrolyte 
multilayered (PEM) films, they have demonstrated a general platform for in vivo 
transfection and nanoparticle co-delivery that preserves the activity of bioactive molecules. 
This combination addresses the challenge of targeted delivery to APCs by exploiting their 
relative abundance in the skin, where they are two times more abundant than in the 
circulation 18, to boost vaccine efficacy. The platform can potentially reduce the strain on 
vaccine manufacturing via dose sparing 19 of current vaccine formulations and by enabling 
the use of DNA vaccines, which can exploit the superior transport properties of a PEM film-
coated microneedle device to overcome the poor immunogenic responses elicited with 
traditional IM delivery methods. In addition, solid-state stabilization can alleviate logistical 
concerns related to stockpiling and distribution by allowing for stable room temperature 
storage of solid as opposed to liquid formulations 20-24. When compared to hypodermic 
needles, the use of microneedle arrays can also lower costs to a healthcare system by 
reducing the incidence of sharps related injuries and allowing for self-administration of a 
vaccine patch where there is a lack of trained medical personnel 23. These features of the 
layer-by-layer (LbL) assembled PEM film microneedle arrays make the technology 
attractive for commercialization, which will be the focus of this paper.  
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2 Background 
 
2.1 Current Vaccine Options 
 
A successful vaccine is marked by adherence to several design criteria including safety, 
cost, efficacy, and level of invasiveness to administer 25. Since Jenner’s observations more 
than two centuries ago of immunity that a related infection can confer, the concept of a live-
attenuated vaccine has been applied to numerous other pathogens including polio, 
chickenpox, and yellow fever. (Table 2) Efforts to improve the safety profile of the first 
vaccines resulted in Pasteur’s findings over a century ago of the effects of administering a 
killed pathogen to elicit an immune response and led to development of vaccines based on 
whole-killed pathogens to treat illnesses including whooping cough, typhoid fever, and 
influenza. Further efforts to improve safety and efficacy have employed reductionist 
principles for eliciting immunity and have resulted in the development and use of purified or 
recombinant subunit vaccines for indications such as HPV and meningococcus. Ongoing 
efforts over the last two centuries have indeed resulted in ever-safer vaccines; however, not 
all of these improvements have resulted in equal progress for all design criteria. 
 
Table 2: Sample of disease targets and method used to generate vaccine 1 
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2.1.1 Live-Attenuated Vaccines 
 
The concept behind a live-attenuated vaccine lies in separating illness-causing virulence 
from factors stimulating protective immunity. If virulence can be decoupled from a 
pathogen, a live-attenuated vaccine typically elicits strong immunogenic responses from its 
qualities as an invasive organism capable of efficient delivery to the cytosol, generating 
antigens for a memory response, and displaying pathogen-associated molecular patterns 
(PAMP) to provoke an innate response 1. These qualities provoke the infected host into 
treating the attenuated organism as a serious threat and mounting robust humoral and 
cellular immune responses to clear the pathogen. 
The attenuation process to generate a live-attenuated vaccine typically starts by 
subjecting the pathogen to non-ideal growth conditions and selecting for variants of the 
strain that are viable. In the case of influenza, attenuation involves growth at lower than 
ideal temperatures to select for temperature sensitive mutants. Since the attenuation process 
relies on the generation of viable but weakened mutants that are less able to cause disease, 
the process may not ever achieve a suitable strain that successfully decouples virulence from 
the invasive properties of the organism. In addition, attenuated strains risk reversion to a 
virulent form by acquiring mutations in the wild or encountering wild-type strains after 
distribution, which raises concerns for both consumers of the vaccine and healthcare 
providers who administer the vaccine 26. 
  
2.1.2 Whole-Killed Vaccines 
 
Another general strategy to generate vaccines is via killing or inactivating a pathogen. 
This procedure permanently disables the ability of the pathogen to invade, replicate, and 
cause disease. When a killed pathogen is administered as a vaccine, its antigens are still 
available to provoke an immune response via class II antigen presentation that APCs use to 
sample the extracellular space. Disabling of the invasive properties removes the reversion 
risk when exposed to the environment, which makes whole-killed vaccines preferable when 
compared to an attenuated vaccine formulation for vulnerable populations.  
While whole-killed vaccines are perceived to be safer than live-attenuated vaccination 
strategies, issues with efficacy are more pronounced. The lack of in vivo activity for an 
inactivated pathogen preferentially activates a skewed immune response resulting in 
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primarily humoral immunity and the generation of antibodies. This biased reaction results in 
poor cell-mediated immunity and the poor activation of cytotoxic T-cells (CTLs), which is 
important for sustained and effective long-term immunity to the pathogen in question. The 
inability to replicate in vivo also renders a whole-killed vaccine ineffective at provoking a 
strong immune response without an adjuvant to achieve adequate activation of APCs 1.  
 
2.1.3 Subunit Vaccines 
 
Purified and recombinant subunit vaccines take the concept of a whole-killed or 
inactivated vaccine one step further by isolating or exogenously expressing in another 
organism the immune stimulating epitopes from a pathogen and administering the purified 
antigens as a vaccine. The strategy has the advantage of removing harmful debris that may 
stimulate unwanted side effects from a whole-killed preparation and has no risk of causing 
disease. Similar to a whole-killed vaccine, subunit vaccines may also suffer from poor 
immunogenicity from the lack of in vivo activity and PAMP to generate a balanced immune 
response and may require an adjuvant or chemically conjugated carrier protein to be added 
to the final vaccine formulation 1.  
 
2.1.4 Manufacturing for Mass Distribution 
 
Manufacturing processes of existing vaccine technologies, while mature in the ability to 
produce a highly pure compound, lacks the ability to scale to higher production capacities at 
a low enough cost and a short enough timeframe for prompt worldwide distribution. In the 
case of the influenza vaccine, which uses an egg-based production process to produce a 
whole-killed formulation, large-scale production of the vaccine is extremely time-
consuming and labor-intensive but the economics of the influenza vaccine preclude 
investment in alternative means of production. Under the most optimistic scenarios and a 
production timeframe of one year, approximately 17% of the world population can be 
covered; a timeframe of almost five years is required for 100% worldwide coverage (Table 
3). The relatively short timeframe for the spread of a novel pathogen such as H5N1 avian 
influenza would have had a devastating effect on the human population by the time enough 
vaccine were produced to take advantage of herd immunity effects, making any effort to 
stem the spread of a particularly virulent and infectious strain a task with a bleak outlook.  
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Table 3: Worldwide manufacturing capacity and time needed to achieve population coverage 1 
 
 While the production process for attenuated, whole-killed, or subunit vaccines is 
relatively straightforward since cultures can be expressed to high concentrations with 
existing technologies 1, major issues remain that require assessment of alternatives to stem 
the spread of unanticipated outbreaks. In the case of attenuated vaccines, not all pathogens 
are amenable to attenuation. For pathogens that can be attenuated, the process can be very 
labor and time intensive, which would make it a poor candidate for controlling a fast-
spreading novel pathogen in the wild. Both whole-killed and subunit processes generate 
relatively safe vaccines but are poorly immunogenic without an adjuvant and primarily 
skews a normally balanced response between humoral and cellular immune reactions. In 
addition, the poor immunogenicity frequently requires large doses of a vaccine in 
conjunction with an adjuvant to elicit protective levels of immunity, which can strain a 
production and distribution chain for a rapidly spreading novel pathogen. Downstream 
manufacturing, especially in the case for subunit vaccines, can be an enormous bottleneck 
exacerbated by higher than expected dosing requirements. In combination, increased dosage 
and processing exerts upward pressure on pricing, narrowing the market for a vaccine 
product to populations that can bear the cost burden. Innovation that can blend the 
effectiveness of a live-attenuated strain with the safety of subunit vaccines at an accessible 
price point with low production lead times would be well equipped to flourish in the present 
and foreseeable market. 
 
2.2 DNA Vaccines 
 
Introduced in the early 1990’s, the concept of a DNA vaccine was presented as a 
technically simple means of inducing robust humoral and cellular immune responses against 
pathogens and tumor antigens 27-30. With promises to eliminate reversion concerns 
associated with the use of live-attenuated pathogens 31 and contamination risks during the 
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manufacture of whole-killed vaccine stocks, 32 high hopes were placed on the generalized 
platform for combating the most vexing chronic and infectious disease problems of the day 
including cancer, influenza, malaria, hepatitis B, and HIV. However, the concept proved too 
early for its time and early clinical trials in humans for these targets failed to demonstrate 
effective levels of immunity but did generate enough data to demonstrate the safe nature of 
the platform 33-38. Advances over the last two decades to improve the immunogenicity of the 
platform have begun to address the initial shortcomings of the original design. 
While the exact means by which DNA vaccines are capable of eliciting protective levels 
of humoral and cellular immunity in vivo is still under investigation 9, idealized mechanistic 
schematics exist outlining its mechanism of action (Figure 3). After delivery and uptake, the 
delivered plasmid DNA is thought to enter the nucleus of a transfected cell and direct the 
production of the encoded antigen of interest. Depending on the cell type transfected, the 
antigens produced by the delivered plasmid engage both the type I and type II presentation 
pathways to activate APCs via interaction with MHC I and II receptors to direct 
proliferation of CD8+ and CD4+ in lymph nodes and select for antigen-specific CTLs and 
B-cells. The activated CTLs and plasma cells direct a robust immune response to mobilize 
the host immune system to fight off the pathogen or tumor cells of interest. 
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Figure 3: Mechanism of action for DNA vaccines 9 
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Initially deemed a failure after results of early clinical trials yielded poor effectiveness 
data, DNA vaccines have made a comeback in the last five years with products licensed for 
use in small and large animals (Table 1) including fish, dogs, pigs, and horses. Research 
activity to translate the successes in large animals to humans remains intense as the allure of 
a truly universal, effective, safe, and easily mass producible vaccine (Table 5) draws 
researchers to work on the multifaceted challenges related to boosting expression in a 
human subject. Areas that have been targeted include plasmid optimization, gene 
optimization, formulation and immune plasmid optimization, and delivery vehicle 
optimization (Figure 2). Among the areas that are currently targets for research, 
optimization of the delivery method poses the greatest technical challenge with the largest 
amount of diversity and variability in the means that the challenge can be resolved. Initial 
trial failures can be partly attributed to the lack of alternative delivery methods to administer 
DNA beyond a traditional IM injection, which has been shown to transfect mostly 
myocytes, a cell type that is located beyond the APC-rich regions of the skin. Studies have 
shown the importance of transfecting APCs to generate a potent immune response 12-13 and 
these findings have directed the development of next-generation delivery methods that target 
the skin directly.  
 
 
Table 5: Qualities of a DNA vaccine 9 
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2.3 Vaccine Delivery 
 
The predominant mode of vaccine delivery has been and continues to be by needle and 
syringe. The World Health Organization estimates that approximately 12 billion needle 
injections are administered worldwide where 5% of that total accounts for immunization-
related injections 39. Despite refined protocols for administration, this mature but antiquated 
delivery technique is not without its risks, with the most prominent concern resting in safety 
from needle pricks for the healthcare provider and the reuse and spread of disease from 
improperly used or reused needles for patients and the community. Recent geopolitical and 
pandemic events have placed renewed focus on immunization and the resource-, and labor-
intensive nature for the proper handling of the needle and syringe, especially in developing  
nations where the population is already predisposed to increased morbidity and mortality 
from infectious agents (Figure 4) and it is estimated that 50% of all injections are given in 
an unsafe manner 40.  
 
 
Figure 4: Mortalities per year from unsafe injections 39 
 
In addition to the safety and resource matters that pervade the use of needles and 
syringes, there are also issues of compliance with recommended vaccination schedules, fears 
of pain from a needle prick, and general convenience matters related to the proper 
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administration of a needle and syringe delivered vaccine 41 that drives patients away from 
being proactive about receiving their vaccinations and plays an important role in changing 
morbidity and mortality for populations in developing countries. Cost also plays a very 
important role in motivating the design of alternative delivery methods for vaccinations. 
While the materials cost for an injection amounts to $0.06, the social costs of increased risks 
of infection and the need for trained personnel to administer an injection increases resource 
outlays more than 450-fold to $26.77 per injection 42. In addition, needle syringe delivery 
obligates the use of liquid formulations that require a cold chain to sustain vaccine integrity 
at a worldwide annual cost of between $200 and $300 million that can be redirected to 
vaccinating 100 million more children annually 43. These factors combined have catalyzed 
innovation in the field to change the standard of needle and syringe delivery with promising 
results. Among the alternatives to an IM injection with a needle and syringe are delivery 
candidates that target mucosal and cutaneous surfaces.  
Mucosal delivery of vaccine was first practiced centuries ago in China with the nasal 
delivery of smallpox scabs and oral delivery of fleas from cows infected with cowpox as a 
means to prevent smallpox 44. However, the field was not brought to prominence until the 
1960’s with the introduction of Sabin’s oral polio vaccine, which has since resulted in 
several vaccines developed exclusively for use on mucosal surfaces including the influenza 
nasal spray. Other mucosal surfaces of interest include pulmonary and vaginal or rectal 
surfaces; however, the inherent qualities of mucosal surfaces as the first line of defense 
against insults from the environment has made development of effective vaccines difficult 
without the use of strong adjuvants. In addition, mucosal surfaces frequently display high 
levels of degradative enzymatic activity, making the delivery of intact antigens difficult 
(Table 6).  
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Table 6: Needle-free delivery methods 44 
 
Potent systemic and mucosal responses elicited through cutaneous immunization have 
made skin immunization a desirable means by which to prevent infection at the point of 
entry 45-46. Skin immunization offers an effective means to elicit robust CD8+ CTL mucosal 
responses simultaneously in the gut, lung, saliva, and the female reproductive tract 47. 
Cutaneous immunization is thus vastly superior to traditional immunization routes including 
intramuscular or intranasal techniques that typically elicit compartmentalized mucosal 
responses specific to a subset of the surfaces stimulated via cutaneous immunization 45.  
Cutaneous delivery vehicles designed to take advantage of the robust immune response have 
had a long history of development since the introduction of the liquid-jet injector (Table 6). 
However, its usefulness as an alternative to the needle and syringe is limited because of the 
same risks of infection and contamination in common with needles as well as the high cost 
associated with the device 44,48. An alternative developed to better target APCs for 
intracellular delivery was embodied in epidermal powder devices that propel dried 
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formulations under high pressure. While powder injectors enhanced targeting for more 
efficacious delivery (Table 6), the devices also suffered from the same drawbacks as liquid-
jet injectors and needles at significantly higher costs 44,48.  
Recent efforts for cutaneous delivery have focused on topical delivery devices that 
attempt to permeate the outermost layers of the skin to make the skin more amenable for 
delivery of small molecules and biologics. Initial efforts have focused on passive delivery 
patches but these devices were limited to small molecules that were readily diffusible past 
the stratum corneum layers of the skin 44,49. Iterations of the platform have made it possible 
to deliver higher molecular weight compounds and biologics but at the cost of adding strong 
adjuvants and permeabilizing agents such as cholera toxin 44,49, which comes with risks such 
as inflammation and damage from retrograde transport to neuronal cell bodies, causing 
unintended side effects to the central nervous system 50. Most recently, efforts have been 
focused on electroporation as a candidate for reversible physical disruption of the stratum 
corneum and success has been documented with the delivery of a peptide into the skin of a 
mouse that generated a strong CTL response 51. Positive results for the electroporation 
platform has been documented in small and large animals for the transcutaneous 
administration of therapeutic genes 9 although complexities with device design have 
inhibited study in humans 49.  
An alternative effort at cutaneous delivery has focused on microneedle patches dip-
coated with small molecule or biologic compounds 49. These devices have been shown to be 
painless or near painless by careful design of short micrometer projections that do not 
penetrate the dermis where pain receptors are found 52 (Figure 5). However, dip-coating 
comes with many disadvantages including limited control of delivery kinetics and the 
relatively few molecules that stay active after a drying process 16. Iterations of the concept 
have resulted in the production of a dissolvable microneedle array molded from biologically 
compatible monomers and cross-linked to encapsulate a vaccine payload 53. However, 
photopolymerization with UV light to form the final array precludes the use of more 
sensitive biomolecules such as DNA due to photochemical damage 54 to the payload, 
restricting the range of compounds that a dissolving microneedle patch can deliver. Recent 
efforts in thin film engineering have sought to deal with the challenge of coatings on 
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micrometer surfaces while preserving bioactivity of a therapeutic agent 55 and results point 
to a generalizable platform for potent and cost effective vaccine delivery vehicle 17.  
 
 
Figure 5: Delivery methods in development to replace needle and syringe delivery of vaccines 44 
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3 Invention Overview 
 
3.1 Motivation 
 
Transdermal delivery has been extensively studied as an alternative to mucosal delivery 
and hypodermic needle injection of drugs and vaccines. The ease of access and stratification 
of bioactive layers 17 makes the skin a very desirable target for immunization and has been 
the focus of innovative solutions that aim to permeabilize this robust barrier for the delivery 
of bioactive compounds. One solution that has garnered much attention involves the use of 
microneedle patches composed of micrometer arrays of projections coated with thin films of 
dried drug or biologic formulations 15,56-58 that efficiently permeabilizes the stratum corneum 
to deliver the coated compounds directly to APCs. However, the use of a dry-coat dipping 
process has inherent disadvantages that prevent uniform deposition and controllable release 
kinetics 16. Another proposed solution for transcutaneous delivery involves the use of 
dissolvable microneedle arrays that release its encapsulated contents upon application of the 
microneedle patch 53. However, UV photopolymerization to crosslink the polymer matrix 
during production has been shown to damage sensitive biomolecules such as DNA 54, which 
places a limitation on the breadth of biomolecules that this platform can deliver.  
Recent work in the field of PEM thin film engineering has demonstrated the versatility of 
self-assembled films to encapsulate small molecules and biologics, enabling control over 
release kinetics and solid-state stabilization of coated compounds on the nanometer scale 16-
17,21-22,59-60. However, cutaneous patches require a means of disrupting the stratum corneum 
of the skin for the delivery of larger and more charged compounds such as DNA. The 
synergy of PEM thin films deposited on microneedle arrays would combine efficient and 
pain-free disruption of the stratum corneum with the superior release kinetics and solid-state 
stabilization intrinsic to PEM films. As a combination platform, this PEM film-coated 
microneedle device would be ideal for the delivery of vaccines, small molecules, and other 
biologics.  
 
 
3.2 Device Fabrication 
 
Fabrication of the PEM film-coated microneedle arrays requires serial processing of the 
raw constituents to form the final device. While most bench-scale processes require 
 29 
 
retooling and adaptation of methods for mass manufacture, the utilization of processes 
prevalent in microelectronics and techniques refined to fabricate microfluidic devices for the 
fabrication of this coated microneedle device would most likely only require swapping of 
fabrication machinery to accommodate higher throughput in an industrial process. 
 
3.2.1 Poly(lactide-co-glycolide) Microneedle Array 
 
Poly(lactide-co-glycolide) (PLGA), a biocompatible and biodegradable copolymer 
compound, was used as the raw starting material to fabricate the microneedle arrays. A 
polydimethylsiloxane (PDMS) mold was fabricated and laser ablated to the required depth 
and geometry to serve as a reusable negative mold. PLGA pellets were then placed on the 
PDMS surface and the PLGA-loaded mold was placed in a vacuum oven for 40 minutes at 
145o C. After melting into the mold, the microneedle-mold device was placed in a -20o C 
freezer for 1 hour to allow for solidification before separation (Figure 6). Microneedle 
devices fabricated in this way yielded PLGA arrays with either pyramidal or conical 
geometry and needle lengths ranging from 800 to 1200 µm. For the purposes of this study, a 
needle length of 900 µm was selected (Figure 7).  
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Figure 6: Schematic for the production of PLGA microneedle arrays from a PDMS mold 17 
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Figure 7: Microneedle arrays with pyramidal (left) and conical (right) cross sections 17 
 
 
3.2.2 Polyelectrolyte Multilayered Thin Film Coatings 
 
After separation of the PLGA microneedle device from the PDMS mold, the microneedle 
surfaces were treated in plasma cleaner with O2 plasma for 2 minutes. The PLGA 
microneedle array was then dipped in an alternating fashion into a solution of protamine 
sulfate (PS) and poly(4-styrene sulfonate) (SPS) for 10 and 5 minutes respectively with 
intervening 1 minute rinses with deionized water to provide a uniform surface charge 
density for PEM functional layer deposition. Following 20 coats of PS/SPS, plasmid DNA 
was deposited on the PS/SPS coated microneedle surfaces by dipping in the same fashion as 
described above but alternating with polymer-1, a hydrolysable polyelectrolyte in the 
poly(B-amino ester) family, in 5 minute dipping intervals separated by 30 second rinsing 
steps with deionized water to achieve an alternating stacked structure of cationic and anionic 
charges that self assemble onto the microneedle surface (Figure 8). Lipid-coated PLGA 
nanoparticles were also deposited onto the PS/SPS prepared surfaces in an alternating 
fashion with polymer-1 but via an airbrush spray method for 3 seconds punctuated by 6 
second deionized water rinse sprays. Spray coating followed by dip-coat deposition of the 
microneedle surfaces was also attempted and combination plasmid DNA/lipid-coated PLGA 
nanoparticle delivery arrays were studied as a platform for concurrent DNA and 
nanoparticle delivery. 
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Figure 8: Alternating polycation and polyanion coating strategy for layer-by-layer assembly of thin films 
17 
 
3.3 PEM Microneedle Performance 
 
3.3.1 Delivery Performance 
 
Delivery performance of the DNA and/or nanoparticle loaded microneedle arrays was 
visualized using a MHC II-GFP transgenic mouse model that expresses an in situ marker for 
discerning viable epidermis. Microneedle devices were placed on the dorsal ear skin of the 
mouse model and delivery performance was visualized with fluorescent confocal 
microscopy after applications for 1 min, 5 min, and 24 hours. Delivery kinetics for labeled 
DNA-loaded microneedle arrays differed from that of nanoparticle-loaded arrays (Figure 9). 
Insertion of the DNA-loaded microneedle array for short time periods (5 min) revealed poor 
delivery characteristics as shown in Figure 9A whereas a 24 hour insertion period revealed 
highly localized and efficient delivery into the viable epidermis (Figure 9B), suggesting that 
the polymer-1 layers require time for hydrolytic degradation to release the DNA cargo. 
Nanoparticle-loaded microneedle arrays were found to deliver nanoparticles even after a 5-
minute insertion period as shown in Figure 9C, suggesting that the act of inserting the 
microneedle is associated with nanoparticle delivery. When the microneedle array was 
coated with nanoparticles followed by DNA, controlled delivery of nanoparticles and DNA 
was observed after 24 hours as shown in Figure 9D, suggesting that the profile of the thin 
film should be a design criterion dependent on the delivery application.  
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Figure 9: Confocal microscopy for visualizing delivery of labeled DNA and labeled nanoparticles by 
microneedle application to the dorsal ear skin of transgenic MHC II-GFP fusion mouse. A) DNA loaded 
array applied for 5 minutes B) DNA array applied for 24 hours C) Lipid-coated nanoparticle array applied 
for 5 minutes D) DNA/lipid-coated NP co-delivery after 24 hour application 17 
 
3.3.2 Transfection Performance 
 
DNA transfection performance was evaluated with a DNA-coated microneedle device 
carrying a plasmid expressing the firefly luciferase gene. Transfection was evaluated for 
different coating densities (1, 5, 24 bilayers) and at two times (5 minutes and 24 hours) 
(Figure 10). When comparing Figures 10A and 10D, there is a notable time dependence for 
transfection of a 24-bilayer coated microneedle array that correlates well with the co-
localization trend observed with the delivery of labeled DNA in Figures 9A and 9B. In 
addition, there was a discernable difference in expression level between mice treated  with 
an array loaded with more DNA as measured in the differences in luminescence between 
mice in Figures 10B, 10C, and 10D. Mice treated with an array loaded with 1-bilayer 
(Figure 10B) showed no expression whereas mice treated with arrays loaded with 24-
bilayers (Figure 10D) showed strong luciferase expression. These findings indicate that 
dosage can be tuned with modification of simple parameters to suit the needs of the desired 
delivery application.  
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Figure 10: Bioluminescence assay to visualize transfection efficiency of pLUC loaded microneedle 
arrays. A) 24-bilayer applied for 5 minutes. B) 1-bilayer applied for 24 hours. C) 5-bilayers applied for 24 
hours. D) 24-bilayers applied for 24 hours 17 
 
3.4 Suitability and Market Potential as a Vaccine Delivery Platform 
 
The Hammond and Irvine groups have demonstrated a proof of concept device that 
synergizes the permeabilizing efficiency of a microneedle array with the versatility of PEM 
thin films coatings. Tunable layer-by-layer deposition of DNA and/or nanoparticles allows 
for robust control of dosing and release kinetics, a feature absent or lacking in dip coated 
and dissolvable microneedle arrays. In addition, the conditions for deposition of thin films 
are mild and do not require the use of drying or radiation to produce the final product, 
expanding the range of molecules that can be encapsulated in a PEM thin film-coated array 
to include fragile biomolecules.  
  Initial characterization of the device on viable murine dorsal ear epidermis with 
fluorescently labeled cargo showed co-localization of delivered cargo with epidermal 
Langerhans cells, which is indicative of successful delivery at the proper depth to induce an 
immunogenic response. Subsequent characterization with an in vivo transfection assay 
demonstrated stable DNA transfection by a microneedle-supported PEM film, a key finding 
that allows for the translation of this device to vaccination-related uses for the delivery of a 
DNA vaccine.  
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4 Market Dynamics and Commercialization Strategy 
 
4.1 Global Vaccine Market 
 
Traditionally a high cost, low profit margin segment, the pharmaceutical industry has 
found renewed interest in the vaccine market and have begun to invest in the segment since 
the blockbuster introduction of Prevnar, a 7-valent conjugate vaccine for pneumococcal 
infections, by Wyeth in 2000 61. With the rise of critical public health issues in the face of 
H1N1, H5N1, and the specter of bioterrorism, pharmaceutical giants have begun a 
conversion to hybrid biotechnology/pharmaceutical companies to take advantage of the 
growth opportunities through mergers and acquisitions of key market players including 
Chiron by Novartis in 2006 and Wyeth by Pfizer in 2009. Attrition from this high cost 
vaccine industry, especially after the 1980 introduction of good manufacturing practices 
(GMP), has thinned the number of market players significantly from over a dozen in 1967 to 
five major players that control almost 90% of the market 62: Novartis, GlaxoSmithKline, 
Merck, Sanofi-Pasteur, and Pfizer 61. 
While the global vaccine market accounted for only 2.8% of pharmaceutical industry 
revenue of $21.28 billion in 2008, revenue is expected to grow with a compound annual 
growth rate (CAGR) of 12.1% in the global market to over $47 billion in 2015 62 (Figure 
11). Emerging markets such as India, China, and Brazil are becoming key drivers for 
revenue growth as the government finds renewed focus in public vaccination campaigns 62.  
 
 
Figure 11: Global vaccine market revenue projections from 2008-2015 62 
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4.2 Industry Challenges for Incumbent and Potential Market Players 
 
Growth potential in the vaccine market remains high and is expected to grow at a 
sustained rate but the path to higher revenues remains rocky. Major barriers to entry and/or 
growth include crushing upfront capital expenditures, a highly fragmented global market, 
and the absence of healthcare infrastructure in developing nations for effective penetration 
of the market. These barriers are not insurmountable for emerging players but do require 
large amounts of capital and is a strong deterrent for smaller players that aim to challenge 
the 89.8% market share amongst the market leaders 62.    
For aspiring market entrants planning to tap into this growth sector, large investment 
outlays are required at the outset for manufacturing capabilities since the introduction of 
GMP and the requirement to document and validate each step in the supply chain. Because 
vaccines are typically produced in or are parts of living organisms, FDA regulatory 
guidelines pose an enormous barrier for entrants that attempt to penetrate to market with a 
new product since there is an approximately 15-year lag time before market approval 62.  
A highly fragmented market also poses a challenge for both established and aspirant 
vaccine manufacturers. A patchwork of differing regulatory guidelines, price controls, and 
monopsony purchasing power of governments in developing countries and Europe pose 
challenges for maximizing revenue, especially for a startup (Table 7). 
While developing nations possess enormous growth potential for vaccines, inadequate or 
non-existing healthcare infrastructure poses a challenge for getting any product to market no 
matter the size of the company. By far, the greatest issue remains the maintenance of the 
cold chain, the low temperature storage needed for most biologics until the point of use. 
Manufacturing and delivery innovation that can alleviate this barrier can be extremely 
attractive to existing market players and can be used as leverage for a small company with 
the proper intellectual property holdings looking to penetrate the market due to the cost 
savings and disruption of the current supply chain model this innovation may have 17,43,62-63.  
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Table 7: Challenges in vaccine market 62 
 
4.3 Initial Analysis of Intellectual Property  
 
For any innovation to succeed on the market, clear intellectual property (IP) rights need 
to be established in order to attract sources of funding as this is the only way to ensure that a 
market exists for a return on investment. The patentability of the PEM thin film-coated 
degradable microneedle device was assessed through a patent and literature search. 
 
4.3.1 Patents Related to Microneedle Arrays 
 
Extensive patent coverage has already been issued for the use and manufacture of 
polymer microneedle arrays. Patent 6,334,856 held by the Georgia Tech Research 
Corporation describes a microneedle device that is extensively similar to the device 
employed by the Irvine and Hammond system 64. Among the most substantial claims that 
prevent the use and manufacture of a polymer microneedle device includes claims 1 and 23, 
which are especially vague in its claims to any microneedle device constructed from a 
polymer. In addition, extensive coverage of the molding process including the use of polymer 
to make the mold and the use of laser ablation to generate the holes used to make the 
microstructures is covered in claims 2, 5, and 22.  
In addition to claims made in patent 6,334,856, a follow-up patent application number 
20090131905 65 was filed on 5/21/2009 that attempts to expand the coverage of the uses and 
manufacture of microneedle devices. In this patent application, Allen, et al. clarify their 
claims to polymer microneedle devices to include biodegradable polymers composed of 
poly(hydroxy acid)s, polyanhydrides, poly(ortho)esters, polyurethanes, poly (butyric acid)s, 
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poly(valeric acid)s, and poly(lactide-co-caprolactone)s. While the Irvine and Hammond 
microneedle platform uses a polymer that is not specifically covered in this claim, a literature 
search revealed public disclosures 66 by Allen, et al. documenting use of PLGA 
microneedles. Depending on the outcome of the new patent application and its claims to the 
use of other classes of biodegradable polymers, licensing of this patent may be required. 
 
4.3.2 Patents Related to Microneedle Coatings 
 
In the realm of coated microneedle structures, patent application 20080213461 67 has 
been filed by Gill et al. claiming coverage for coatings that are composed of at least one drug 
and a viscosity enhancer. The restriction of the use of a drug and a viscosity enhancer should 
post no threat to the patentability of the Irvine and Hammond system as neither a drug nor a 
viscosity enhancer was used. A point of caution should be noted if further development 
requires a means of securing a microneedle array to the skin with adhesive; claim 65 
specifically claims the use of adhesive material between two or more needles in the array. 
This claim poses a minor annoyance if it remains in final approval since a different means of 
fixating the device to the skin, if needed for complete delivery, may need to be developed.  
 
4.3.3 Patents Related to Thin Films 
 
Methods for constructing decomposable thin films of polyelectrolytes and their uses has 
been patented in patent 7,112,361 68 by a group that includes Professors Hammond and 
Langer at MIT. This patent provides broad coverage of the alternating polycation and 
polyanion structure similar to the scheme used in the Irvine and Hammond system. The 
patent also provides coverage for deposition of this film on polymer substrates. Hammond, et 
al. has also further clarified claims to self-assembled thin film structures in patent application 
20080311177 55  to lay claim to films that self assemble specifically with proteins and drugs. 
The Irvine and Hammond microneedle system employs a PEM thin film structure that layers 
DNA and lipid-coated nanoparticles, which is not explicitly claimed by patent 7,112,361 or 
patent application 20080311177. The wording of both patents covering decomposable thin 
films, however, should not be of any issue as Hammond is a collaborator for this PEM film 
coated microneedle system and will be an integral part of any commercialization process.  
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4.3.4 Patents Related to Manufacturing Processes 
 
Issues related to the patentability of certain manufacturing processes associated with the 
Irvine and Hammond microneedle array tie back to the IP surrounding polymer microneedle 
arrays described in patent 6,334,856 issued to Allen, et al. of Georgia Tech. The patent 
provides broad coverage for a mold-produced microneedle array composed of a polymer. 
Patent application 20090131905 further excludes the use of degradable polymers that are not 
already in the public domain. Licensing of this technology may likely need to happen if 
innovation to circumvent the existing patent and patent application does not occur.  
 
4.3.5 Patents Related to Vaccines and Targets 
 
At its core, the PEM film-coated microneedle array is a delivery vehicle and offers no 
therapeutic benefit on its own. In order to confer therapeutic qualities to the microneedle 
device, an IP portfolio for particular antigen targets and/or vaccine candidates must be 
obtained. Since the development of an IP portfolio for antigen targets and DNA vaccines is 
not a core competency, it would be very time- and cost-prohibitive. A strategic partnership to 
license an IP portfolio of disease targets would be the most effective solution. 
 
4.4 Market Strategy for Commercialization 
 
With the assumption that the initial analysis of intellectual property revealed most of the 
major roadblocks to successful commercialization of the Irvine and Hammond microneedle 
system, the IP holdings for this delivery system would be most amenable to 
commercialization via a strategic partnership with a pharmaceutical company and with the 
stakeholders at Georgia Tech while grouping all the IP holdings into an intellectual property 
licensing company. This partnership would be mutually beneficial for all parties involved. 
Pharmaceutical companies have large portfolios of disease and antigen targets that can be 
adapted for use in a DNA plasmid delivered in a vaccine formulation. Georgia Tech’s 
holdings for the underlying microneedle device would be inadequate if used in its current 
form to controllably deliver a plasmid for transcutaneous delivery. This gap can be bridged 
with the patent holdings between Irvine and Hammond for a LbL PEM film coating that can 
be self-assembled onto the surface of a degradable polymer microneedle.  
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Once suitable partners that possess disease target portfolios, negotiations should take 
place for the disease target IP holders to acquire a non-exclusive license to use the Irvine and 
Hammond system for the delivery of the vaccine candidate. In this way, the IP surrounding 
the Irvine and Hammond platform will not be limited to the disease targets with earlier 
partners and the company holding the IP for the Irvine and Hammond delivery system would 
be able to maximize revenue. Once the rights to use the IP from the disease target holders are 
acquired, the company should work to maximize the efficient delivery of the construct and 
contract with a contract manufacturing organization to produce this specific formulation. The 
pharmaceutical partners who hold the rights to the disease target antigens would then use the 
formulations produced by the contract manufacturing organization to conduct clinical trials, 
which can also be outsourced if the pharmaceutical partners wish to do so.  
This business arrangement would be optimal for the Irvine and Hammond holding 
company as all partners would be involved with their core competencies. The Irvine and 
Hammond holding company would be charged with optimizing the layered film formulations 
and then passing this formulation to a contract manufacturer, which would have the expertise 
to produce the devices at a large scale and at low cost. The IP for the target vaccine that did 
not have a feasible delivery vehicle that the pharmaceutical partners held would now have an 
effective delivery vehicle for use in clinical trials, a core competency that requires resources 
that a large pharmaceutical company would already possess. In this way, the Irvine and 
Hammond IP holding company and the pharmaceutical partners would be able to minimize 
risk throughout the entire process. The lack of a need to develop manufacturing facilities 
would drastically reduce costs related to capital expenditure, the primary barrier for 
competitors to the main players in the vaccine market.  
 
4.4.1 Value-Added in the Vaccine Supply Chain 
 
In order to be a successfully commercialized technology, there has to be an incentive for 
the existing market players to employ the novel technology. One of the main benefits of the 
Irvine and Hammond microneedle delivery platform is the solid-state stabilization of the 
loaded vaccine, which has enormous implications for reducing cost throughout the supply 
chain. The pharmaceutical partners that participate in the joint venture would be able to 
reduce logistical costs associated with ensuring the vaccine does not spoil at ambient 
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temperatures. The contract manufacturing partners would also be able to reduce overhead 
from the lack of cold chain maintenance throughout the manufacturing process. The savings 
associated with the lack of a cold chain alone can either be converted into higher profits or, if 
the partnership terms allow, enable the sale of the resultant vaccine at significantly lower 
costs and generate good will and publicity for all partners involved in the venture.  
 
4.4.2 Risks of the Commercialization Process  
 
While strategic planning can reduce most of the risks associated with the 
commercialization process, unexpected events should be expected to occur. Variables that 
need to be considered during the commercialization process include the variability that 
contract manufacturing can introduce to the supply chain, regulatory hurdles for approval by 
the FDA, and the long-term investments required to last through a FDA approval process.  
While contract manufacturing can reduce the risks of failure in terms of upfront capital 
costs to all parties, manufacturing by a third party can lead to unintended and unexpected 
variability in the final product. Bench-scale operations typically do not scale well to 
industrial processes and tweaking of the production process for manufacturing may be 
required to achieve feasibility and cost goals. In order to minimize the level of unintended 
roadblocks during the contract manufacturing stage, it would be useful to work closely with 
the contract manufacturing partners to co-develop a process that does not deviate from the 
function of the final device.  
FDA approval for a novel delivery device can be a long and arduous process. Successful 
preclinical data in animals may not translate to successful outcomes in human studies as was 
experienced with first generation DNA vaccines 9. Even in cases where clinical trials uphold 
the data obtained from animal models, unexpected occurrences can take place including 
adverse events and demands for more trial data. Should these occurrences take place, the 
enormous capital outlays that the pharmaceutical partners have budgeted might be exceeded 
and threaten the future of the project. Since these events cannot be predicted with any 
certainty, adequate budgeting and working closely with pharmaceutical partners is the only 
recourse for mitigation.  
Collaborating with a large pharmaceutical company provides the benefits of reduced 
risks, especially for a startup company, but the results of failure are more profound for the 
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startup partner due to limited resources. There is always risk of a disruptive technology that 
can make the delivery platform obsolete before it has a chance to recoup costs from selling 
on the market. It is therefore wise to diversify and recruit a group of pharmaceutical partners 
and target various disease targets to hedge the risk of inevitable failure given the low rates of 
FDA approval 69. 
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5 Conclusion 
 
An evaluation of the polyelectrolyte multilayer thin film-coated microneedle vaccine 
delivery system has been performed throughout this paper. Combining the advantages of a 
microneedle array to permeabilize the stratum corneum in the skin with the superior control 
characteristics of a self-assembling thin film loaded with bioactive cargo, the Irvine and 
Hammond microneedle platform is poised to supplant existing microneedle coating solutions 
that rely on surface tension and drying during manufacture 23. The solid-state stabilization of 
cargo allows for streamlined handling of vaccine formulations by potentially eliminating the 
need for refrigeration and allowing storage at ambient temperatures 16. The ability to 
eliminate the cold chain can confer any vaccine therapeutic with a competitive advantage in 
cost and in logistical concerns for developing nations where an adequate cold chain does not 
exist.  
The intellectual property landscape for this new technology was also discussed in this 
paper. While most of the delivery platform is clear of any potentially infringing elements, the 
need to license intellectual property from Georgia Tech may pose some issues if the 
infringing elements cannot be circumvented. Even if the potential overlap cannot be feasibly 
circumvented, a strategic partnership can and should be formed to add partners to the joint 
venture, which can mitigate risk if FDA approval should fail.  
The case to form a purely intellectual property company was presented in this paper as a 
means to maximize revenue and hedge away most of the potential risks of bringing a new 
biologic and delivery device to market. While contracting out all manufacturing does have 
risks, the consequences of failure far exceed the costs associated with developing expertise 
outside the scope of the company’s core competencies. The proposal to develop a partnership 
should be viable as value is added across the supply chain where all partners stand to gain 
from the efficiencies generated from this delivery platform.  
Risks during the commercialization process were also discussed that may hamper 
progress during a joint venture. While the risk factors may be hard to hedge away, especially 
in the case of the FDA approval process, this should not deter the company from attempting 
the joint venture as the technology underpinning the delivery platform is sound and has the 
potential to disrupt the status quo for vaccine delivery in a positive manner.  
 43 
 
References 
 
1. Ulmer, J.B., Valley, U. & Rappuoli, R. Vaccine manufacturing: challenges and solutions. 
Nat Biotech 24, 1377-1383 (2006). 
2. Cooper, M.R., Stewart, D.C., Kahl, F.R., Brown, W.M. & Cordell, A.R. Medicine at the 
medical center then and now: One hundred years of progress. South.Med.J. 95, 1113-
1121 (2002). 
3. Global Polio Eradication Initiative. Bull. World Health Organ. 84, 595-595 (2006). 
4. Wassilak, S. & Orenstein, W. Challenges faced by the global polio eradication initiative. 
Expert Review of Vaccines 9, 447-449 (2010). 
5. Webby, R.J. & Webster, R.G. Are We Ready for Pandemic Influenza? Science 302, 
1519-1522 (2003). 
6. Check, E. Avian flu special Is this our best shot? Nature 435, 404-406 (2005). 
7. Hehme, N., Engelmann, H., Kuenzel, W., Neumeier, E. & Saenger, R. Virus Res. 103, 
163-171 (2004). 
8. Epidemic Alert and Response: Vaccines for Pandemic Influenza. Summary Report.  
(World Health Organization, 2004). 
9. Kutzler, M.A. & Weiner, D.B. DNA vaccines: ready for prime time? Nat. Rev. Genet. 9, 
776-788 (2008). 
10. Rice, J., Ottensmeier, C.H. & Stevenson, F.K. DNA vaccines: precision tools for 
activating effective immunity against cancer. Nat. Rev. Cancer 8, 108-120 (2008). 
11. Buchan, S. Electroporation as a 'prime/boost' strategy for naked DNA vaccination against 
a tumor antigen. J. Immunol. 174, 6292-6298 (2005). 
12. Porgador, A., et al. Predominant Role for Directly Transfected Dendritic Cells in Antigen 
Presentation to CD8+ T Cells after Gene Gun Immunization. The Journal of 
Experimental Medicine 188, 1075-1082 (1998). 
13. Condon, C., Watkins, S.C., Celluzzi, C.M., Thompson, K. & Falo, L.D. DNA-based 
immunization by in vivo transfection of dendritic cells. Nat Med 2, 1122-1128 (1996). 
14. Danko, I., et al. High expression of naked plasmid DNA in muscles of young rodents. 
Hum. Mol. Genet. 6, 1435-1443 (1997). 
15. Gill, H.S. & Prausnitz, M.R. Coated microneedles for transdermal delivery. Journal of 
Controlled Release 117, 227-237 (2007). 
16. Su, X., Kim, B.-S., Kim, S.R., Hammond, P.T. & Irvine, D.J. Layer-by-Layer-Assembled 
Multilayer Films for Transcutaneous Drug and Vaccine Delivery. ACS Nano 3, 3719-
3729 (2009). 
17. DeMuth, P.C., Su, X., Samuel, R.E., Hammond, P.T. & Irvine, D.J. Nano-Layered 
Microneedles for Transcutaneous Delivery of Polymer Nanoparticles and Plasmid DNA. 
Advanced Materials 22, 4851-+ (2010). 
18. Clark, R.A., et al. The Vast Majority of CLA+ T Cells Are Resident in Normal Skin. J 
Immunol 176, 4431-4439 (2006). 
19. Widera, G., et al. Effect of delivery parameters on immunization to ovalbumin following 
intracutaneous administration by a coated microneedle array patch system. Vaccine 24, 
1653-1664 (2006). 
20. Jewell, C.M., Zhang, J., Fredin, N.J. & Lynn, D.M. Multilayered polyelectrolyte films 
promote the direct and localized delivery of DNA to cells. J. Controlled Release 106, 
214-223 (2005). 
 44 
 
21. Kim, B.-S., Park, S.W. & Hammond, P.T. Hydrogen-Bonding Layer-by-Layer-
Assembled Biodegradable Polymeric Micelles as Drug Delivery Vehicles from Surfaces. 
ACS Nano 2, 386-392 (2008). 
22. Macdonald, M., Rodriguez, N.M., Smith, R. & Hammond, P.T. Release of a model 
protein from biodegradable self assembled films for surface delivery applications. J. 
Controlled Release 131, 228-234 (2008). 
23. Prausnitz, M.R., Mikszta, J.A., Cormier, M. & Andrianov, A.K. Microneedle-based 
vaccines. Curr Top Microbiol Immunol 333, 369-393 (2009). 
24. Fuller, D.H., Loudon, P. & Schmaljohn, C. Preclinical and clinical progress of particle-
mediated DNA vaccines for infectious diseases. Methods 40, 86-97 (2006). 
25. Babiuk, S., Baca-Estrada, M., Babiuk, L.A., Ewen, C. & Foldvari, M. Cutaneous 
vaccination: the skin as an immunologically active tissue and the challenge of antigen 
delivery. Journal of Controlled Release 66, 199-214 (2000). 
26. AnneMorris, H., Joseph, A.B. & Max, P.O. Live Attenuated Bacterial Vaccines: New 
Approaches for Safety and Efficacy. The Lancet 325, 1472-1474 (1985). 
27. Tang, D.-c., DeVit, M. & Johnston, S.A. Genetic immunization is a simple method for 
eliciting an immune response. Nature 356, 152-154 (1992). 
28. Ulmer, J., et al. Heterologous protection against influenza by injection of DNA encoding 
a viral protein. Science 259, 1745-1749 (1993). 
29. Wang, B., et al. Gene inoculation generates immune responses against human 
immunodeficiency virus type 1. Proceedings of the National Academy of Sciences of the 
United States of America 90, 4156-4160 (1993). 
30. Fynan, E.F., et al. DNA vaccines: protective immunizations by parenteral, mucosal, and 
gene-gun inoculations. Proceedings of the National Academy of Sciences of the United 
States of America 90, 11478-11482 (1993). 
31. Ruprecht, R.M. Live attenuated AIDS viruses as vaccines: promise or peril? 
Immunological Reviews 170, 135-149 (1999). 
32. Offit, P.A. The Cutter Incident, 50 Years Later. New England Journal of Medicine 352, 
1411-1412 (2005). 
33. Ulmer, J.B., Wahren, B. & Liu, M.A. Gene-based vaccines: recent technical and clinical 
advances. Trends in Molecular Medicine 12, 216-222 (2006). 
34. Le, T.P., et al. Safety, tolerability and humoral immune responses after intramuscular 
administration of a malaria DNA vaccine to healthy adult volunteers. Vaccine 18, 1893-
1901 (2000). 
35. Mincheff, M., et al. Naked DNA and adenoviral immunizations for immunotherapy of 
prostate cancer: A phase I/II clinical trial. European Urology 38, 208-217 (2000). 
36. MacGregor, R.R., et al. First human trial of a DNA-based vaccine for treatment of human 
immunodeficiency virus type 1 infection: Safety and host response. Journal of Infectious 
Diseases 178, 92-100 (1998). 
37. Tacket, C.O., et al. Phase 1 safety and immune response studies of a DNA vaccine 
encoding hepatitis B surface antigen delivered by a gene delivery device. Vaccine 17, 
2826-2829 (1999). 
38. Liu, M.A. & Ulmer, J.B. Human Clinical Trials of Plasmid DNA Vaccines. in Advances 
in Genetics, Vol. Volume 55 (eds. Jeffrey C. Hall, J.C.D.T.F. & Veronica van, H.) 25-40 
(Academic Press, 2005). 
 45 
 
39. Kermode, M. Unsafe injections in low-income country health settings: need for injection 
safety promotion to prevent the spread of blood-borne viruses. Health Promotion 
International 19, 95-103 (2004). 
40. Simonsen, L., Kane, A., Lloyd, J., Zaffran, M. & Kane, M. Unsafe injections in the 
developing world and transmission of bloodborne pathogens: a review. Bull World 
Health Organ 77, 789-800 (1999). 
41. Miller, M.A. & Pisani, E. The cost of unsafe injections. Bull World Health Organ 77, 
808-811 (1999). 
42. Ekwueme, D.U., Weniger, B.G. & Chen, R.T. Model-based estimates of risks of disease 
transmission and economic costs of seven injection devices in sub-Saharan Africa. Bull. 
World Health Organ. 80, 859-870 (2002). 
43. Das, P. Revolutionary vaccine technology breaks the cold chain. Lancet Infect Dis 4, 719 
(2004). 
44. Mitragotri, S. Immunization without needles. Nat. Rev. Immunol. 5, 905-916 (2005). 
45. Belyakov, I.M., Hammond, S.A., Ahlers, J.D., Glenn, G.M. & Berzofsky, J.A. 
Transcutaneous immunization induces mucosal CTLs and protective immunity by 
migration of primed skin dendritic cells. Journal of Clinical Investigation 113, 998-1007 
(2004). 
46. Gockel, C.M., Bao, S.S. & Beagley, K.W. Transcutaneous immunization induces 
mucosal and systemic immunity: a potent method for targeting immunity to the female 
reproductive tract. Mol. Immunol. 37, 537-544 (2000). 
47. Berry, L.J., et al. Transcutaneous immunization with combined cholera toxin and CpG 
adjuvant protects against Chlamydia muridarum genital tract infection. Infection and 
Immunity 72, 1019-1028 (2004). 
48. Giudice, E.L. & Campbell, J.D. Needle-free vaccine delivery. Adv. Drug Deliv. Rev. 58, 
68-89 (2006). 
49. Prausnitz, M.R. & Langer, R. Transdermal drug delivery. Nat. Biotechnol. 26, 1261-1268 
(2008). 
50. van Ginkel, F.W., Jackson, R.J., Yuki, Y. & McGhee, J.R. Cutting Edge: The Mucosal 
Adjuvant Cholera Toxin Redirects Vaccine Proteins into Olfactory Tissues. J Immunol 
165, 4778-4782 (2000). 
51. Zhao, Y.L., et al. Induction of cytotoxic T-lymphocytes by electroporation-enhanced 
needle-free skin immunization. Vaccine 24, 1282-1290 (2006). 
52. Haq, M.I., et al. Clinical administration of microneedles: skin puncture, pain and 
sensation. Biomed Microdevices 11, 35-47 (2009). 
53. Sullivan, S.P., et al. Dissolving polymer microneedle patches for influenza vaccination. 
Nat Med 16, 915-920 (2010). 
54. Cariello, N.F., Keohavong, P., Sanderson, B.J.S. & Thilly, W.G. DNA damage produced 
by ethidium bromide staining and exposure to ultraviolet light. Nucleic Acids Research 
16, 4157-4157 (1988). 
55. Hammond, P.T. & Macdonald, M. Self Assembled Films for Protein and Drug Delivery 
Applications. in USPTO (Massachusetts Institute of Technology (Cambridge, MA, US), 
United States, 2008). 
56. Prausnitz, M.R. Microneedles for transdermal drug delivery. Adv. Drug Delivery Rev. 56, 
581-587 (2004). 
 46 
 
57. Jiang, J., et al. Coated microneedles for drug delivery to the eye. Invest Ophthalmol Vis 
Sci 48, 4038-4043 (2007). 
58. Gill, H.S. & Prausnitz, M.R. Coating formulations for microneedles. Pharm. Res. 24, 
1369-1380 (2007). 
59. Lynn, D.M. Peeling back the layers: Controlled erosion and triggered disassembly of 
multilayered polyelectrolyte thin films. Advanced Materials 19, 4118-4130 (2007). 
60. Jessel, N., et al. Multiple and time-scheduled in situ DNA delivery mediated by Î²-
cyclodextrin embedded in a polyelectrolyte multilayer. Proc. Natl. Acad. Sci. U. S. A. 
103, 8618-8621 (2006). 
61. Sheridan, C. The business of making vaccines. Nat Biotech 23, 1359-1366 (2005). 
62. Global Vaccines Market.  (Frost & Sullivan, 2009). 
63. Weir, E. & Hatch, K. Preventing cold chain failure: vaccine storage and handling. CMAJ 
171, 1050 (2004). 
64. Allen, M.G., Prausnitz, M.R., Mcallister, D.V. & Cros, F., Paul Marcel. Microneedle 
devices and methods of manufacture and use thereof.  (ed. USPTO) (Georgia Tech 
Research Corporation (Atlanta, GA), United States, 2002). 
65. Allen, M.G., Prausnitz, M.R., Mcallister, D.V. & Cros, F., Paul Marcel. Microneedle 
devices and methods of manufacture and use thereof.  (ed. USPTO) (Georgia Tech 
Research Corporation (Atlanta, Georgia), United States, 2009). 
66. Park, J.H., Allen, M.G. & Prausnitz, M.R. Polymer microneedles for controlled-release 
drug delivery. Pharmaceutical Research 23, 1008-1019 (2006). 
67. Gill, H.S. & Prausnitz, M.R. Coated Microstructures and Methods of Manufacture 
Thereof.  (ed. USPTO) (Georgia Tech Research Corporation (Atlanta, GA, US), United 
States, 2008). 
68. Lynn, D.M., Vazquez, E., Langer, R. & Hammond, P.T. Methods of making 
decomposable thin films of polyelectrolytes and uses thereof. in USPTO (Massachusetts 
Institute of Technology (Cambridge, MA, US), United States, 2006). 
69. Czerepak, E.A. & Ryser, S. Drug approvals and failures: implications for alliances. 
Nature Reviews Drug Discovery 7, 197-198 (2008). 
 
 
